Markets:

Overview

News

Currencies

International

Treasuries

23andMe Holding Co. - Common Stock (NQ:ME)

0.6063 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 23andMe Holding Co. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Dow Tumbles Over 100 Points; US Initial Jobless Claims Fall Last Week ↗

February 08, 2024

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.29% to 38,565.98 while the NASDAQ rose 0.26% to 15,796.91. The...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 08, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 07, 2024

Via Benzinga

Recap: 23andMe Holding Q3 Earnings ↗

February 07, 2024

Via Benzinga

23andMe Reports Third Quarter Fiscal 2024 Financial Results

February 07, 2024

Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473

From 23andMe, Inc.

Via GlobeNewswire

Earnings Scheduled For February 7, 2024 ↗

February 07, 2024

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.

Via Benzinga

A Preview Of 23andMe Holding's Earnings ↗

February 06, 2024

Via Benzinga

Why Is Invitae (NVTA) Stock Down 75% Today? ↗

February 05, 2024

Although genetic testing specialist Invitae forwarded a compelling idea, the lack of business substance ultimately cratered NVTA stock.

Via InvestorPlace

SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy ↗

February 05, 2024

Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures.

Via Benzinga

Topics Bankruptcy

Troubled Biotech Company's Investigational Cancer Drug Gets Greenlighted By FDA ↗

January 31, 2024

This development marks a significant milestone for 23andMe, a company that has been in the spotlight for security breaches in the past.

Via Benzinga

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

January 31, 2024

From 23andMe, Inc.

Via GlobeNewswire

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

January 30, 2024

“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country

From 23andMe, Inc.

Via GlobeNewswire

23andMe Faces Class Action Lawsuit Over Alleged Privacy Breach Targeting Chinese And Ashkenazi Jewish Customers ↗

January 27, 2024

23andMe faces a class-action lawsuit for a privacy breach affecting 7 million customers, particularly Chinese and Ashkenazi Jewish customers.

Via Benzinga

Topics Lawsuit

23andMe to Report FY2024 Third Quarter Financial Results

January 24, 2024

From 23andMe, Inc.

Via GlobeNewswire

The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them ↗

January 21, 2024

Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them.

Via The Motley Fool

23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts

December 19, 2023

From 23andMe, Inc.

Via GlobeNewswire

23andMe Reveals Hackers Accessed 'Significant Number' Of DNA Records ↗

December 02, 2023

23andMe confirmed that hackers accessed around 14,000 customer accounts and an undisclosed number of files containing users' ancestry data.

Via Benzinga

Topics Hacking

The 3 Best Digital Health Stocks for Personalized Medicine ↗

November 25, 2023

Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health.

Via InvestorPlace

23andMe Reports Second Quarter Fiscal 2024 Financial Results

November 08, 2023

Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin

From 23andMe, Inc.

Via GlobeNewswire

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

November 07, 2023

The Company’s first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection

From 23andMe, Inc.

Via GlobeNewswire

23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

November 06, 2023

From 23andMe, Inc.

Via GlobeNewswire

23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data

October 31, 2023

23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe

From 23andMe, Inc.

Via GlobeNewswire

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

October 30, 2023

Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe...

From 23andMe, Inc.

Via GlobeNewswire

23andMe to Report FY2024 Second Quarter Financial Results

October 25, 2023

From 23andMe, Inc.

Via GlobeNewswire

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

October 23, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END

Via FinancialNewsMedia

The Top 7 Stocks to Own During a Downturn ↗

October 11, 2023

Investors tend to get jittery in October but these seven stocks to own during a downturn will protect your portfolio

Via InvestorPlace

23andMe Under Siege: Hacker Reportedly Steals Millions Of Profiles In Genetic Data Heist ↗

October 07, 2023

An unidentified hacker reportedly claims to have stolen personal genetic data from millions of 23andMe Holding Co. (NASDAQ: ME) customer accounts, sparking concerns over privacy and security.

Via Benzinga

Topics Hacking

23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting

September 27, 2023

23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies

From 23andMe, Inc.

Via GlobeNewswire

23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program

September 14, 2023

From 23andMe, Inc.

Via GlobeNewswire

AI Integration In Biotech & Pharma: Companies Positioned To Benefit ↗

September 11, 2023

The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.